Longeveron Inc. (LGVN)
NCM · Healthcare · Biotechnology
$0.78
+1.56%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$23.6M
Shares Outstanding
30.1M
P/S (TTM)
19.4x
Exchange
NCM
Currency
USD
About Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 316K | 137K | 365K | 398K |
| Gross Profit | 146K | 125K | 257K | 264K |
| Operating Income | -5.4M | -7.3M | -5.4M | -4.8M |
| Net Income | -5.0M | -7.2M | -5.4M | -4.7M |
| Diluted EPS | $-0.33 | $-0.39 | $nan | $-0.19 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.2M | 709K | 2.4M | 1.2M |
| Gross Profit | 497K | 221K | 1.9M | 803K |
| Operating Income | -18.0M | -21.0M | -16.5M | -23.3M |
| Net Income | -18.8M | -21.4M | -16.0M | -22.7M |
| Diluted EPS | $-9.00 | $-10.22 | $-2.62 | $-1.29 |